VYNE Therapeutics Inc.
VYNE
$0.36
-$0.01-2.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.29% | -2.06% | 43.03% | 18.16% | 39.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.29% | -2.06% | 43.03% | 18.16% | 39.27% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 6.29% | -2.06% | 43.03% | 18.16% | 39.27% |
| SG&A Expenses | -14.58% | -13.13% | -8.69% | -1.37% | 5.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.96% | 37.50% | 47.69% | 48.70% | 24.14% |
| Operating Income | 1.06% | -38.12% | -47.75% | -49.14% | -23.97% |
| Income Before Tax | 0.47% | -38.26% | -47.94% | -42.80% | -15.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.46% | -38.27% | -47.95% | -42.82% | -15.14% |
| Earnings from Discontinued Operations | 321.82% | 95.77% | 95.32% | 95.34% | 97.98% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.98% | -35.59% | -45.11% | -40.00% | -5.56% |
| EBIT | 1.06% | -38.12% | -47.75% | -49.14% | -23.97% |
| EBITDA | -447.14% | -126.37% | 5.87% | 56.25% | 77.54% |
| EPS Basic | 7.84% | 64.91% | 81.75% | 86.65% | 91.56% |
| Normalized Basic EPS | 3.24% | 61.31% | 81.18% | 86.33% | 90.80% |
| EPS Diluted | 7.84% | 64.91% | 81.75% | 86.65% | 91.56% |
| Normalized Diluted EPS | 3.24% | 61.31% | 81.18% | 86.33% | 90.80% |
| Average Basic Shares Outstanding | 7.42% | 42.50% | 111.95% | 314.58% | 1,142.83% |
| Average Diluted Shares Outstanding | 7.42% | 42.50% | 111.95% | 314.58% | 1,142.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |